ArticleScientific reports2025
FZD6 mediates the contributing role of miR-199a-5p in the adipogenesis of bone marrow mesenchymal stem cells derived from aplastic anemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Accumulating evidence indicates that enhanced adipogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs) derived from aplastic anemia (AA) could contribute to the excessive fat accumulation in the bone marrow. However, the underlying molecular mechanism remains to be determined. Here in this study, we further characterized the contributing role of miR-199a-5p in adipogenesis of AA BM-MSCs through specific inhibition of miR-199a-5p expression. Subsequently, we performed a systematic screening of the downstream targets of miR-199a-5p through web tool prediction, profiling data analysis, and experimental validation, with FZD6 and CELSR1 identified as the most promising targets of miR-199a-5p in the adipogenesis of AA BM-MSCs. Finally, we mainly focused on FZD6, which presents prominently decreased expression in adipogenic differentiation and AA BM-MSC samples and negatively correlates with miR-199a-5p expression. Besides, FZD6 is demonstrated as a negative regulator of adipogenesis of BM-MSCs, and overexpression of FZD6 alleviates the facilitating role of miR-199a-5p in the adipogenic differentiation of BM-MSCs. Overall, our findings provide further mechanistic insights into miR-199a-5p-mediated enhanced adipogenesis of AA BM-MSCs, implicating miR-199a-5p and FZD6 as potential intervention targets for improving BM-MSC-mediated microenvironments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.